about
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domainReduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cellsNon-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.Preclinical development of metalloproteasis inhibitors in cancer therapy.Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.Antiangiogenic and antivascular therapy for cancer.Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.IDN 5390: a new concept in taxane development.Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles.Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds.Snail levels control the migration mechanism of mesenchymal tumor cells.Targeting angiogenesis with compounds from the extracellular matrix.Current understanding of the thrombospondin-1 interactome.Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2.Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.Potential antagonism of tubulin-binding anticancer agents in combination therapies.Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells.Increased tumorigenicity and invasiveness of C6 rat glioma cells transfected with the human alpha-2,8 sialyltransferase cDNA.Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.Matrigel promotes retinoblastoma cell growth in vitro and in vivo.Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium.Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFβ and in cooperation with PDGF.Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues.Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled DiseaseThe calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2)Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma
P50
Q24300120-1980D24B-B6F3-4A3C-BCDF-A47661B8822BQ27316195-D0386DD4-27AC-4507-912F-0EE682FCCC1BQ30493655-596468A3-CDBF-4142-9428-0C48B36D0A0CQ34133632-193B2D3B-7168-4294-B120-8C93F76DC4E5Q34273824-4938A2C9-4303-4D9D-A46B-91472A0F17D3Q34441111-DFDEF7A1-441D-4A10-968C-9292D6676C06Q35052151-49188E12-AF9D-4BE4-971F-9122353646EFQ35101284-8A625977-C8FF-4A24-B8E4-311DE46FAB80Q35965295-4836A9AD-32F3-4A6B-9B68-0AA585765123Q36282749-795008C6-A182-4E59-A761-BDAB80190E00Q36611295-8ED03110-E547-4EF6-B2EA-4A01A74262FAQ36640223-95FF8C3B-4DA1-4BF6-A13F-8CDCFEE813D0Q36951737-78DA550A-C3AC-436D-9A16-D6DA87FA930AQ37002667-4F1421F5-29E8-43C9-B0AA-5D4F35C0CE8BQ37921881-9E0D419E-728A-45E1-BCD3-41F08FA05C2FQ38183216-51D4C530-E4F4-4BE6-AF5E-ABE7AE150323Q38974266-4260CB9B-FD04-4716-93B0-4E61783DDF4FQ39104708-C38CD366-0C85-42DE-92A4-189D84CF7E74Q39220203-5E6CD065-0E58-4FDE-AAF6-7F0D7075DB07Q39261197-1A7CD670-C91E-494C-815C-C115968AFCAEQ39768357-A296761B-F273-4FC3-90C8-C2474E888539Q40438018-2838DDA8-7CE8-4077-BA51-66B212C03F72Q40677359-09B8B2D2-2305-4B03-88B5-9AB34AB5E568Q40868315-404E977D-DE62-436F-B1D9-71700D029044Q40931019-0E104076-5EF1-4FA9-A0DE-0A34331DC9F0Q42757110-8E0A5836-9B55-4BD4-8CF2-3DCAD706AAF3Q42835129-36055026-4FBE-4E5E-8C8E-85C8A78D5666Q42855929-6616254C-7623-4EF0-927D-12F9818FC553Q44427260-1683A4E0-B4D1-4AC3-A75C-7CACC656C0C7Q47779887-D6B91376-C86A-4BAC-8329-60E929392EDEQ47858500-A48D1CE4-EA22-4528-B21F-0909C36BD18CQ50773969-78E7CEA6-476D-432B-B4F0-E2BBC284E905Q51136254-98AAA1A2-45EC-448F-80F2-27E0D8A7EAB0Q53421812-B8FC95F6-F7D3-43B5-AAEE-B1AA47660E15Q53518575-0D46C59B-C4D2-48FA-9852-1C82ABE3CA7DQ54378807-BA3548B3-BA3B-44D1-BD99-B1B180F767D3Q54798858-44F9BA2A-692A-4352-A4CD-54CB78403339Q56942842-78A1A4D2-3E72-49E1-9218-8B73101544EEQ57166615-B0D65335-A6E5-4811-977D-FF6AA7E7C081Q57758506-27F5B1D3-CA33-43CB-B680-813B8DEB4BAD
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giulia Taraboletti
@ast
Giulia Taraboletti
@en
Giulia Taraboletti
@es
Giulia Taraboletti
@nl
Giulia Taraboletti
@sl
type
label
Giulia Taraboletti
@ast
Giulia Taraboletti
@en
Giulia Taraboletti
@es
Giulia Taraboletti
@nl
Giulia Taraboletti
@sl
prefLabel
Giulia Taraboletti
@ast
Giulia Taraboletti
@en
Giulia Taraboletti
@es
Giulia Taraboletti
@nl
Giulia Taraboletti
@sl
P106
P1153
7004198521
P21
P31
P496
0000-0001-8780-5001